Zhejiang Xianju PharmaceuticalLtd Past Earnings Performance
Past criteria checks 2/6
Zhejiang Xianju PharmaceuticalLtd has been growing earnings at an average annual rate of 13.3%, while the Pharmaceuticals industry saw earnings growing at 9.4% annually. Revenues have been growing at an average rate of 3.7% per year. Zhejiang Xianju PharmaceuticalLtd's return on equity is 9.9%, and it has net margins of 13.8%.
Key information
13.3%
Earnings growth rate
11.1%
EPS growth rate
| Pharmaceuticals Industry Growth | 10.9% |
| Revenue growth rate | 3.7% |
| Return on equity | 9.9% |
| Net Margin | 13.8% |
| Last Earnings Update | 31 Mar 2024 |
Revenue & Expenses BreakdownBeta
How Zhejiang Xianju PharmaceuticalLtd makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 4,204 | 581 | 1,307 | 288 |
| 31 Dec 23 | 4,123 | 563 | 1,264 | 261 |
| 30 Sep 23 | 4,164 | 692 | 1,289 | 255 |
| 31 Mar 23 | 4,288 | 755 | 1,443 | 251 |
| 01 Jan 23 | 4,380 | 749 | 1,536 | 267 |
| 30 Sep 22 | 4,493 | 689 | 1,571 | 237 |
| 30 Jun 22 | 4,442 | 676 | 1,597 | 241 |
| 31 Mar 22 | 4,405 | 636 | 1,588 | 249 |
| 01 Jan 22 | 4,357 | 619 | 1,560 | 243 |
| 30 Sep 21 | 4,402 | 605 | 1,478 | 232 |
| 30 Jun 21 | 4,391 | 573 | 1,472 | 232 |
| 31 Mar 21 | 4,276 | 548 | 1,418 | 232 |
| 31 Dec 20 | 4,019 | 505 | 1,335 | 208 |
| 30 Sep 20 | 3,873 | 478 | 1,381 | 228 |
| 30 Jun 20 | 3,620 | 442 | 1,307 | 215 |
| 31 Mar 20 | 3,618 | 420 | 1,363 | 210 |
| 31 Dec 19 | 3,709 | 410 | 1,430 | 205 |
| 30 Sep 19 | 3,741 | 381 | 1,503 | 169 |
| 30 Jun 19 | 3,723 | 352 | 1,497 | 161 |
| 31 Mar 19 | 3,628 | 319 | 1,483 | 146 |
| 31 Dec 18 | 3,622 | 301 | 1,474 | 143 |
| 30 Sep 18 | 3,514 | 277 | 1,421 | 124 |
| 30 Jun 18 | 3,337 | 249 | 1,313 | 135 |
| 31 Mar 18 | 3,116 | 231 | 1,227 | 107 |
| 31 Dec 17 | 2,853 | 207 | 1,133 | 88 |
| 30 Sep 17 | 2,671 | 187 | 1,088 | 47 |
| 30 Jun 17 | 2,572 | 168 | 1,096 | 0 |
| 31 Mar 17 | 2,547 | 149 | 1,089 | 0 |
| 31 Dec 16 | 2,504 | 146 | 1,045 | 0 |
| 30 Sep 16 | 2,457 | 135 | 962 | 0 |
| 30 Jun 16 | 2,504 | 123 | 945 | 0 |
| 31 Mar 16 | 2,441 | 108 | 900 | 0 |
| 31 Dec 15 | 2,480 | 107 | 877 | 0 |
| 30 Sep 15 | 2,466 | 88 | 846 | 0 |
| 30 Jun 15 | 2,461 | 71 | 851 | 0 |
| 31 Mar 15 | 2,473 | 60 | 826 | 0 |
| 31 Dec 14 | 2,471 | 57 | 796 | 0 |
| 30 Sep 14 | 2,408 | 45 | 809 | 0 |
| 30 Jun 14 | 2,370 | 38 | 727 | 0 |
| 31 Mar 14 | 2,373 | 51 | 671 | 0 |
| 31 Dec 13 | 2,315 | 61 | 655 | 0 |
| 30 Sep 13 | 2,326 | 78 | 641 | 0 |
| 30 Jun 13 | 2,194 | 103 | 624 | 0 |
Quality Earnings: 002332 has high quality earnings.
Growing Profit Margin: 002332's current net profit margins (13.8%) are lower than last year (17.6%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 002332's earnings have grown by 13.3% per year over the past 5 years.
Accelerating Growth: 002332's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 002332 had negative earnings growth (-23%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-1.5%).
Return on Equity
High ROE: 002332's Return on Equity (9.9%) is considered low.